IRIS
RIMINI, MARGHERITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.923
NA - Nord America 2.826
AS - Asia 2.510
SA - Sud America 467
Continente sconosciuto - Info sul continente non disponibili 235
AF - Africa 49
OC - Oceania 8
Totale 9.018
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.674
RU - Federazione Russa 1.609
SG - Singapore 833
CN - Cina 735
IT - Italia 508
BR - Brasile 382
RO - Romania 263
BD - Bangladesh 261
HK - Hong Kong 239
VN - Vietnam 225
FR - Francia 120
DE - Germania 102
GB - Regno Unito 80
SE - Svezia 72
CA - Canada 71
IN - India 61
MX - Messico 37
JP - Giappone 35
NL - Olanda 34
AR - Argentina 32
FI - Finlandia 27
AT - Austria 25
PL - Polonia 24
ZA - Sudafrica 22
ES - Italia 19
IQ - Iraq 14
TR - Turchia 14
ID - Indonesia 13
JM - Giamaica 13
CO - Colombia 10
EC - Ecuador 10
MA - Marocco 10
CL - Cile 9
LT - Lituania 9
AU - Australia 8
IE - Irlanda 8
MY - Malesia 8
VE - Venezuela 8
NP - Nepal 7
PK - Pakistan 7
SA - Arabia Saudita 7
EG - Egitto 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
CR - Costa Rica 5
HN - Honduras 5
PH - Filippine 5
UY - Uruguay 5
UZ - Uzbekistan 5
PY - Paraguay 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
UA - Ucraina 4
AZ - Azerbaigian 3
BO - Bolivia 3
KR - Corea 3
LB - Libano 3
NI - Nicaragua 3
PR - Porto Rico 3
SI - Slovenia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
DZ - Algeria 2
IL - Israele 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
OM - Oman 2
PT - Portogallo 2
SR - Suriname 2
AG - Antigua e Barbuda 1
AL - Albania 1
BM - Bermuda 1
BW - Botswana 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CM - Camerun 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
JO - Giordania 1
KE - Kenya 1
KY - Cayman, isole 1
LK - Sri Lanka 1
MM - Myanmar 1
MV - Maldive 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
SX - ???statistics.table.value.countryCode.SX??? 1
TH - Thailandia 1
TN - Tunisia 1
Totale 8.784
Salva come PNG Salva come JPEG
Città #
Dallas 956
Singapore 500
Moscow 327
Ashburn 269
Hong Kong 231
San Jose 186
Beijing 168
New York 140
Council Bluffs 117
Milan 94
Los Angeles 89
Ho Chi Minh City 88
Shanghai 78
Lauterbourg 77
Santa Clara 73
Hefei 64
Rome 51
Hanoi 46
Orem 36
São Paulo 32
Naples 29
Tokyo 29
Munich 28
Boardman 27
Chicago 23
Montreal 23
London 22
Nuremberg 21
Brooklyn 20
Guangzhou 20
Poplar 20
Warsaw 20
Denver 19
Lawrence 19
Princeton 19
Stockholm 19
Toronto 19
Buffalo 18
Cesano Boscone 17
Helsinki 17
Mexico City 17
Da Nang 16
Frankfurt am Main 16
Rio de Janeiro 15
Vienna 15
Atlanta 14
Manchester 14
Chennai 13
Houston 13
Johannesburg 13
Phoenix 13
Romagnano Sesia 13
Boston 12
Biên Hòa 11
Bari 10
Kingston 10
Monza 10
Mumbai 10
Newark 10
Bologna 9
Dhaka 9
Lappeenranta 9
Philadelphia 9
Washington 9
Amsterdam 8
Catania 8
Haiphong 8
Secaucus 8
Shenzhen 8
Belo Horizonte 7
Dublin 7
Florence 7
Milwaukee 7
Omaha 7
Porto Alegre 7
San Francisco 7
Verona 7
Ankara 6
Bacoli 6
Brasília 6
Changsha 6
Falkenstein 6
Figino 6
Genoa 6
Kolkata 6
Padua 6
Palermo 6
Queens 6
Seattle 6
Tianjin 6
Buenos Aires 5
Columbus 5
Kuala Lumpur 5
Montevideo 5
New Delhi 5
North Bergen 5
Querétaro 5
St Louis 5
Tashkent 5
West Palm Beach 5
Totale 4.565
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 437
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 422
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 351
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 147
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 141
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 140
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 135
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 123
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 123
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 122
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 122
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 122
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 122
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 122
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 117
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 116
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 116
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 115
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 115
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 115
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 114
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 111
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 111
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 107
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 105
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 105
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 104
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 103
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 103
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 103
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 103
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 101
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 98
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 97
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 95
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 94
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 93
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center 92
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 91
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 90
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 89
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 89
Cholangiocarcinoma: new perspectives for new horizons 88
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 88
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 85
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 85
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 85
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 84
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 83
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 81
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 80
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 78
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 78
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 76
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 76
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 75
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 74
Clinical implications of malnutrition in the management of patients with pancreatic cancer: Introducing the concept of the nutritional oncology board 74
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 73
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 72
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 68
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3) 67
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 67
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 66
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 66
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 65
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 65
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 65
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 64
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases 64
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 62
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 62
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 62
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT 61
Lenvatinib as a therapy for unresectable hepatocellular carcinoma 60
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 60
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 59
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 59
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 59
Child Pugh and ALBI grade: past, present or future? 58
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 58
Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 57
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 57
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation 55
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 53
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 51
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 45
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 45
Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development 44
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 43
Radial and Longitudinal Margins in Surgery of Perihilar Cholangiocarcinoma: When R1 Definition Is Associated with Different Prognosis 43
Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines 43
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? 43
External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study 38
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study 36
Il trattamento del carcinoma squamocellulare cutaneo localmente avanzato e metastatico 31
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 27
Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer 19
null 7
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 4
Totale 9.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.518
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.518
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 1 0 0 2 12 2 0 0 1
2022/2023118 42 20 4 1 1 22 7 7 8 2 1 3
2023/2024224 12 3 31 18 13 50 3 15 0 5 24 50
2024/20251.228 92 27 18 13 38 91 384 140 122 79 62 162
2025/20266.886 385 685 814 737 527 225 426 468 1.543 285 339 452
2026/2027539 308 231 0 0 0 0 0 0 0 0 0 0
Totale 9.018